These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 32589865)

  • 1. Lenvatinib and pembrolizumab in advanced gastric cancer.
    Cascinu S
    Lancet Oncol; 2020 Aug; 21(8):1004-1005. PubMed ID: 32589865
    [No Abstract]   [Full Text] [Related]  

  • 2. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial.
    Makker V; Rasco D; Vogelzang NJ; Brose MS; Cohn AL; Mier J; Di Simone C; Hyman DM; Stepan DE; Dutcus CE; Schmidt EV; Guo M; Sachdev P; Shumaker R; Aghajanian C; Taylor M
    Lancet Oncol; 2019 May; 20(5):711-718. PubMed ID: 30922731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pembrolizumab plus lenvatinib for all advanced endometrial cancer? Maybe not.
    Paulino E
    Int J Gynecol Cancer; 2022 Apr; 32(4):579. PubMed ID: 35190462
    [No Abstract]   [Full Text] [Related]  

  • 4. [New drug approval: Pembrolizumab plus lenvatinib in second line for patients with advanced or recurrent endometrial cancer].
    De Jesus C; Rodrigues M
    Bull Cancer; 2022; 109(7-8):740-741. PubMed ID: 35672187
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical Benefit from Lenvatinib and Pembrolizumab Observed in Mullerian Adenosarcoma: A Case Report.
    Alcindor T; Jung S; Gilbert L
    Curr Oncol; 2021 Jun; 28(3):2146-2149. PubMed ID: 34200874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Durable response with lenvatinib and pembrolizumab combination therapy in a patient with pre-treated metastatic cholangiocarcinoma.
    Dreikhausen L; Kusnik A; Schulte N; Eckardt M; Teufel A; Gaiser T; Ebert M; Zhan T
    J Gastrointestin Liver Dis; 2021 Sep; 30(3):409-410. PubMed ID: 34551034
    [No Abstract]   [Full Text] [Related]  

  • 7. Acute heart failure during lenvatinib plus pembrolizumab therapy.
    Nakazawa H; Yamaguchi S
    Int J Gynecol Cancer; 2022 Jun; 32(6):817. PubMed ID: 35667674
    [No Abstract]   [Full Text] [Related]  

  • 8. Lenvatinib plus Pembrolizumab for Renal Cell Carcinoma.
    Hindié E
    N Engl J Med; 2021 Jul; 385(3):287. PubMed ID: 34260845
    [No Abstract]   [Full Text] [Related]  

  • 9. Lenvatinib plus Pembrolizumab for Renal Cell Carcinoma. Reply.
    Motzer R; Choueiri TK
    N Engl J Med; 2021 Jul; 385(3):287. PubMed ID: 34260846
    [No Abstract]   [Full Text] [Related]  

  • 10. Response of advanced HCC to pembrolizumab and lenvatinib combination therapy despite monotherapy failure.
    Schulte N; Li M; Zhan T; Dreikhausen L; Sollors J; Antoni C; Diehl S; Schoenberg SO; Rahbari N; Reissfelder C; Giordano FA; Ebert MP; Teufel A
    Z Gastroenterol; 2020 Aug; 58(8):773-777. PubMed ID: 32785913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pembrolizumab for the treatment of gastric cancer.
    Kamath SD; Kalyan A; Benson AB
    Expert Rev Anticancer Ther; 2018 Dec; 18(12):1177-1187. PubMed ID: 30280940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Initial Experience of Ramucirumab Treatment After Lenvatinib Failure for Patients With Advanced Hepatocellular Carcinoma.
    Kuzuya T; Ishigami M; Ito T; Ishizu Y; Honda T; Ishikawa T; Fujishiro M
    Anticancer Res; 2020 Apr; 40(4):2089-2093. PubMed ID: 32234901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lenvatinib: Role in thyroid cancer and other solid tumors.
    Cabanillas ME; Habra MA
    Cancer Treat Rev; 2016 Jan; 42():47-55. PubMed ID: 26678514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial.
    Shitara K; Özgüroğlu M; Bang YJ; Di Bartolomeo M; Mandalà M; Ryu MH; Fornaro L; Olesiński T; Caglevic C; Chung HC; Muro K; Goekkurt E; Mansoor W; McDermott RS; Shacham-Shmueli E; Chen X; Mayo C; Kang SP; Ohtsu A; Fuchs CS;
    Lancet; 2018 Jul; 392(10142):123-133. PubMed ID: 29880231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma.
    Liu Z; Lin Y; Zhang J; Zhang Y; Li Y; Liu Z; Li Q; Luo M; Liang R; Ye J
    J Exp Clin Cancer Res; 2019 Nov; 38(1):447. PubMed ID: 31684985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival benefit with second-line combination in endometrial cancer.
    Romero D
    Nat Rev Clin Oncol; 2022 Mar; 19(3):149. PubMed ID: 35087212
    [No Abstract]   [Full Text] [Related]  

  • 17. FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD-L1.
    Fashoyin-Aje L; Donoghue M; Chen H; He K; Veeraraghavan J; Goldberg KB; Keegan P; McKee AE; Pazdur R
    Oncologist; 2019 Jan; 24(1):103-109. PubMed ID: 30120163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer drug trials show modest benefit: drugs target liver, gastric, head and neck cancers.
    Hampton T
    JAMA; 2007 Jul; 298(3):273-5. PubMed ID: 17635880
    [No Abstract]   [Full Text] [Related]  

  • 19. Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma.
    Joshi SS; Maron SB; Catenacci DV
    Future Oncol; 2018 Feb; 14(5):417-430. PubMed ID: 29094609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lenvatinib - A multikinase inhibitor for radioiodine-refractory differentiated thyroid cancer.
    Hewett Y; Ghimire S; Farooqi B; Shah BK
    J Oncol Pharm Pract; 2018 Jan; 24(1):28-32. PubMed ID: 27856921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.